Impact of Metformin Use on Esophageal Cancer Recurrence and Survival: A Systematic Review and Meta-Analysis 369

Introduction: Esophageal cancer (EC) has a poor prognosis, and a growing body of work has suggested links to modifiable metabolic risk factors such as obesity and diabetes. Metformin, a commonly used medication to treat obesity and diabetes, is a known activator of AMP kinase, and can stabilize p53....

Full description

Saved in:
Bibliographic Details
Published inThe American journal of gastroenterology Vol. 113; no. Supplement; pp. S211 - S212
Main Authors Wilder, Evan, Poles, Jillian, Yang, Brooke, Popov, Violeta
Format Journal Article
LanguageEnglish
Published New York Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins 01.10.2018
Subjects
Antidiabetics
Diabetes
Esophageal cancer
Gastroenterology
Medical prognosis
Meta-analysis
Systematic review
Online AccessGet full text

Cover

Be the first to leave a comment!
You must be logged in first